LDLR、APOB和PCSK9罕见遗传变异与主动脉瓣狭窄相关
该研究利用UK Biobank和All of Us的测序与电子健康记录数据,评估LDLR、APOB和PCSK9功能破坏性变异对主动脉瓣狭窄(AS)及主动脉瓣峰值流速的影响。结果显示,LDLR变异携带者LDL-C升高且AS风险增加,而APOB或PCSK9变异携带者LDL-C降低且AS风险降低。结论提示终生较高或较低的LDL-C水平与AS风险分别呈增加和降低关联,早期持续降脂治疗可能延缓或预防AS。
要点
- LDLR功能破坏性变异携带者LDL-C升高,AS风险增加(OR 3.52)。
- APOB或PCSK9功能破坏性变异携带者LDL-C降低,AS风险降低(OR 0.49)。
- LDLR变异携带者主动脉瓣峰值流速更高,PCSK9变异携带者更低。
核心结论
- 终生较高或较低的LDL-C水平分别与主动脉瓣狭窄风险显著增加和降低相关。
- 早期持续降脂治疗可能延缓或预防主动脉瓣狭窄发展。
研究设计与样本
- 研究使用UK Biobank和All of Us的测序数据与电子健康记录,以及UK Biobank的磁共振成像数据。
- 通过LOFTEE和AlphaMissense算法识别预测的蛋白质破坏性变异。
主要发现
- LDLR蛋白质破坏性变异携带者平均LDL-C较高(UKB:+42.6 mg/dL;P=4.4e-237),AS风险增加(荟萃分析:OR 3.52 [95% CI, 2.39-5.20];P=2.3e-10),主动脉瓣置换风险增加(OR 3.78 [95% CI, 2.26-6.32];P=4.0e-7)。
- APOB或PCSK9蛋白质破坏性变异携带者平均LDL-C较低(UKB:-32.3 mg/dL;P<5e-324),AS风险降低(荟萃分析:OR 0.49 [95% CI, 0.31-0.75];P=0.001),主动脉瓣置换风险降低(OR 0.54 [95% CI, 0.30-0.97];P=0.04)。
临床怎么用
- 对于LDLR功能破坏性变异携带者,应关注主动脉瓣狭窄风险并进行评估。
- 对于APOB或PCSK9功能破坏性变异携带者,主动脉瓣狭窄风险较低。
- 早期和持续降脂治疗可能作为延缓或预防主动脉瓣狭窄的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite a proposed causal role for LDL-C (low-density lipoprotein cholesterol) in aortic stenosis (AS), randomized controlled trials of lipid-lowering therapy failed to prevent severe AS. We aimed to assess the impact on AS and peak velocity across the aortic valve conferred by lifelong alterations in LDL-C levels mediated by protein-disrupting variants in 3 clinically significant genes for LDL (low-density lipoprotein) metabolism (LDLR, APOB, and PCSK9). METHODS: We used sequencing data and electronic health records from UK Biobank (UKB) and All of Us and magnetic resonance imaging data from UKB. We identified predicted protein-disrupting variants with the Loss Of Function Transcript Effect Estimator (LOFTEE) and AlphaMissense algorithms and evaluated their associations with LDL-C and peak velocity across the aortic valve (UK Biobank), as well as diagnosed AS and aortic valve replacement (UK Biobank and All of Us). RESULTS: We included 421 049 unrelated participants (5621 with AS) in UKB and 195 519 unrelated participants (1087 with AS) in All of Us. Carriers of protein-disrupting variants in LDLR had higher mean LDL-C (UKB: +42.6 mg/dL; P=4.4e-237) and greater risk of AS (meta-analysis: odds ratio, 3.52 [95% CI, 2.39-5.20]; P=2.3e-10) and aortic valve replacement (meta-analysis: odds ratio, 3.78 [95% CI, 2.26-6.32]; P=4.0e-7). Carriers of protein-disrupting variants in APOB or PCSK9 had lower mean LDL-C (UKB: -32.3 mg/dL; P<5e-324) and lower risk of AS (meta-analysis: odds ratio, 0.49 [95% CI, 0.31-0.75]; P=0.001) and aortic valve replacement (meta-analysis: odds ratio, 0.54 [95% CI, 0.30-0.97]; P=0.04). Among 57 371 UKB imaging substudy participants, peak velocities across the aortic valve were greater in carriers of protein-disrupting variants in LDLR (+12.2 cm/s; P=1.6e-5) and lower in carriers of protein-disrupting variants in PCSK9 (-6.9 cm/s; P=0.022). CONCLUSIONS: Rare genetic variants that confer lifelong higher or lower LDL-C levels are associated with substantially increased and decreased risk of AS, respectively. Early and sustained lipid-lowering therapy may slow or prevent AS development.
引用
- Rämö JT, Jurgens SJ, Kany S, et al. Rare Genetic Variants in LDLR, APOB, and PCSK9 Are Associated With Aortic Stenosis. Circulation. 2024. PMID: 39222019. doi:10.1161/CIRCULATIONAHA.124.070982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。